TICKERNERD
Menu
ARWRARWRHealthcare · Biotechnology

ARWR Stock Forecast: Arrowhead Pharmaceuticals, Inc. Price Predictions for 2026-2027

Last close, 24 Aug 2026
$87
−0.39% on the day

The 12 Wall Street analysts covering Arrowhead Pharmaceuticals, Inc. hold a median 12-month price target of $104 — +19.9% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 59 of 100 as at 22 Aug 2026 — in the upper half.

Market cap
$12.3B
Ticker Nerd rank
59 / 100
Median analyst target
$104
Analysts covering
12
Revenue$75.3M+171.0% y/y
Operating income−$170.1M
Net income−$178.9M
Free cash flow−$181.3M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
−2.2%
1M
+1.4%
YTD
+30.7%
1Y
+306.8%
From 52W high
−3.1%
From 52W low
+319.0%
$21
$90
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

ARWR stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Arrowhead Pharmaceuticals, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 22 Aug 2026
59 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Quality
93
Momentum
92
Value
90
Accruals
74
Volatility
44
Revisions
42
Growth
37
Size
14
Issuance
12

Quality (93): The business earns solid, repeatable profits on what it owns.

Issuance (12): The company has been issuing shares or taking on financing, diluting existing holders.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

ARWR stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on ARWR, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$20$40$60$80$100$120$140Oct 25Jan 26Apr 26Jul 26ARWRHigh $126Median $104Low $100

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says12 analysts
12 Buy0 Hold0 Sell
Low $100Median $104High $126

The green dot is the last close — the median target sits +19.9% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 7 moved their price target up and 0 moved it down.

DateFirmActionRatingTarget
6 Aug 2026HC Wainwright & Co.MaintainsBuy$115 → $120
30 July 2026B. Riley SecuritiesMaintainsBuy$101 → $123
27 July 2026HC Wainwright & Co.MaintainsBuy—
27 July 2026HC Wainwright & Co.MaintainsBuy$100 → $115
23 July 2026Morgan StanleyMaintainsOverweight$100 → $120
23 July 2026Morgan StanleyMaintainsOverweight—
23 July 2026Piper SandlerReiteratesOverweight—
23 July 2026Piper SandlerReiteratesOverweight$110 → $126
22 July 2026Chardan CapitalMaintainsBuy$90 → $115
22 July 2026Chardan CapitalMaintainsBuy—
17 July 2026JP MorganMaintainsOverweight$88 → $95
17 July 2026JP MorganMaintainsOverweight—
14 July 2026StifelInitiatesBuy$98
14 July 2026StifelInitiatesBuy—
1 July 2026HC Wainwright & Co.ReiteratesBuy—
30 June 2026Chardan CapitalMaintainsBuy—
17 June 2026Leerink PartnersMaintainsMarket Perform—
13 May 2026BernsteinMaintainsMarket Perform—
8 May 2026RBC CapitalMaintainsOutperform—
1 May 2026JP MorganInitiatesOverweight—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. ARWR appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

ARWR vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 24 Aug 2026, Arrowhead Pharmaceuticals, Inc. returned +306.8% against +19.6% for the S&P 500, dividends included.

ARWR vs S&P 500, last 12 monthsTotal return, rebased to 100
100200300400Oct 25Jan 26Apr 26Jul 26ARWRS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

ARWR analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
0
Analysts cutting
6
Fundamentals

Arrowhead Pharmaceuticals, Inc. (ARWR) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
47.1×

Cheaper than 16% of US stocks

Price / sales
18.4×

Cheaper than 10% of US stocks

Price / book
26.4×

Cheaper than 4% of US stocks

EV / EBITDA
−60.2×

Cheaper than 95% of US stocks

Growth & margins
Revenue growth (YoY)
171.0%

Higher than 96% of US stocks

Earnings growth (YoY)
171.0%

Higher than 89% of US stocks

Gross margin
—
Operating margin
−226.0%

Higher than 10% of US stocks

Net margin
−47.8%

Higher than 10% of US stocks

Returns & dividend
Return on equity
−55.2%

Higher than 20% of US stocks

Return on assets
−8.1%

Higher than 28% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Arrowhead Pharmaceuticals, Inc. (ARWR) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Arrowhead Pharmaceuticals, Inc. has a market value of $12.3B and an enterprise value of $12.1B.

  • Revenue in the twelve months to 30 June 2026: $669.5M. The latest quarter grew 171.0% year on year.

  • Net income over the same four quarters: −$272.1M, a −40.6% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$75.1M.

  • Shares outstanding: 141.1M.

  • Trailing P/E: 47.1×; forward P/E: −17.9× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Arrowhead Pharmaceuticals, Inc. employs 711 people — $942K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 25 Aug 2026

Data provided by Twelve Data

Peers

ARWR vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
ARWRArrowhead Pharmaceuticals, Inc.$12.3B
59
HALOHalozyme Therapeutics, Inc.$12.3B
97
MDGLMadrigal Pharmaceuticals, Inc.$11.9B
69
BMRNBioMarin Pharmaceutical, Inc.$12.9B
60
CORTCorcept Therapeutics, Inc.$13.1B
80
TECHBio-Techne Corp.$11.3B
94
AXSMAxsome Therapeutics, Inc.$10.7B
74

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Arrowhead Pharmaceuticals, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest ARWR news & analysis

Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress

Business Wire · 24 Aug 2026neutral

Arrowhead Pharmaceuticals announced it will present new clinical data at the European Society of Cardiology Congress (ESC) in Munich, Germany, on August 30, 2026. The presentation will cover 12-month results from the SHASTA-3 and SHASTA-4 pivotal trials of plozasiran in patients with severe hypertriglyceridemia.

Why it matters — Arrowhead watchers would care because this late-breaking presentation provides a venue for pivotal trial data on its lead candidate plozasiran.

People Living with Familial Chylomicronaemia Syndrome (FCS) in Germany Have Access to REDEMPLO® (plozasiran) as a New Treatment Option to Reduce Triglycerides

Business Wire · 17 Aug 2026positive

Arrowhead Pharmaceuticals announced that people in Germany living with Familial Chylomicronaemia Syndrome (FCS) now have access to REDEMPLO (plozasiran), a new treatment to reduce dangerously high triglyceride levels. It follows the European Commission's marketing authorization in June 2026, making German patients among the first in the EU to receive this option.

Why it matters — This marks the commercial availability of Arrowhead's FCS treatment in a major EU market, representing a step in expanding real-world patient access to its approved product.

Arrowhead Pharmaceuticals, Inc. (ARWR) Q3 2026 Earnings Call Transcript

Seeking Alpha · 5 Aug 2026neutral

Seeking Alpha published the transcript of Arrowhead Pharmaceuticals' Q3 2026 earnings call. The excerpt provides no additional details beyond the transcript's availability.

Why it matters — The earnings call transcript gives ARWR watchers a record of management's discussion of the company's quarterly results and outlook.

Arrowhead Pharmaceuticals Q3 Earnings Call Highlights

MarketBeat · 4 Aug 2026positive

On its Q3 earnings call, Arrowhead Pharmaceuticals reported positive Phase III results for plozasiran in severe hypertriglyceridemia, accelerating plans for a supplemental New Drug Application. The company also highlighted continued growth in the launch of its REDEMPLO therapy for familial chylomicronemia syndrome.

Why it matters — For Arrowhead watchers, the positive Phase III data advancing plozasiran and continued REDEMPLO launch growth point to progress in both its pipeline and its commercial rollout.

Arrowhead Pharmaceuticals Reports Fiscal 2026 Third Quarter Results

Business Wire · 4 Aug 2026positive

Arrowhead Pharmaceuticals announced its financial results for the fiscal 2026 third quarter ended June 30, 2026, and is hosting a conference call on August 4, 2026, to discuss them. President and CEO Christopher Anzalone cited recent transformational events supporting continued growth, including recently announced topline results.

Why it matters — ARWR watchers would care because the quarterly report and CEO commentary provide an update on the company's recent clinical developments and its outlook for continued growth.

FAQ

Frequently asked questions about ARWR stock

What is the ARWR stock price forecast for 2026-2027?

The 12 Wall Street analysts covering Arrowhead Pharmaceuticals, Inc. have a median 12-month price target of $104, with estimates ranging from $100 to $126. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is ARWR stock a buy right now?

Of the 12 analysts covering Arrowhead Pharmaceuticals, Inc., 12 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Arrowhead Pharmaceuticals, Inc. 59 out of 100 across roughly 4,600 US stocks as at 22 Aug 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank ARWR?

As at 22 Aug 2026, Arrowhead Pharmaceuticals, Inc. ranks 59 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Quality (93 of 100).

Will ARWR stock go up?

No one can know that. What the data says: the median 12-month target from 12 analysts implies +19.9% from the last close, and Ticker Nerd's factor model ranks Arrowhead Pharmaceuticals, Inc. 59 out of 100 as at 22 Aug 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the ARWR stock forecast for 2030?

No analyst covering Arrowhead Pharmaceuticals, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for ARWR are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $100 to $126 over the next 12 months.

How has ARWR stock performed over the past year?

Arrowhead Pharmaceuticals, Inc. returned +306.8% over the 12 months to 24 Aug 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Arrowhead Pharmaceuticals, Inc. do?

Arrowhead Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing RNA interference-based medicines to treat diseases driven by genetic abnormalities or excess protein production.

What is the latest news on ARWR?

The most recent item we track (Business Wire, 24 Aug 2026): "Arrowhead Pharmaceuticals to Present New Clinical Data at the European Society of Cardiology Congress". Arrowhead Pharmaceuticals announced it will present new clinical data at the European Society of Cardiology Congress (ESC) in Munich, Germany, on August 30, 2026. The presentation will cover 12-month results from the SHASTA-3 and SHASTA-4 pivotal trials of plozasiran in patients with severe hypertriglyceridemia.

Company

About Arrowhead Pharmaceuticals, Inc.

Arrowhead Pharmaceuticals Inc. is a commercial-stage biopharmaceutical company focused on developing RNA interference-based medicines to treat diseases driven by genetic abnormalities or excess protein production. The company uses proprietary RNA chemistries and its TRiM platform to selectively silence disease-causing genes across multiple tissues, including liver, lung, muscle, adipose, and central nervous system. Arrowhead’s portfolio spans cardiometabolic and cardiovascular disorders, liver diseases such as alpha-1 antitrypsin deficiency and hepatitis B, pulmonary conditions including idiopathic pulmonary fibrosis and mucus-obstructive lung disease, and rare genetic diseases affecting muscle and complement-mediated pathways. Its first approved product, REDEMPLO (plozasiran), targets familial chylomicronemia syndrome as an adjunct to diet. Beyond wholly owned programs, Arrowhead also collaborates with large pharmaceutical partners to extend the reach of its RNAi therapeutics globally. Founded in 1989 and headquartered in Pasadena, California, with additional R&D and manufacturing facilities in Wisconsin, San Diego, and Ireland, Arrowhead today operates as a specialized player within the biotechnology and healthcare sectors.

CEO Dr. Christopher R. Anzalone Ph.D. · 711 employees · United States · https://arrowheadpharma.com